IDH wild-type

P1/2, N=70, Terminated, VBI Vaccines Inc. | Recruiting --> Terminated; VBI Bankruptcy

P=N/A, N=42, Recruiting, The Christie NHS Foundation Trust | Not yet recruiting --> Recruiting | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Jul 2025 --> Sep 2026

P1, N=288, Active, not recruiting, AbbVie | Trial completion date: Jun 2026 --> Nov 2027 | Trial primary completion date: Jun 2026 --> Nov 2027

There was no correlation of LAT1 or CD98hc expression with amino acid PET uptake parameters. Further studies to clarify the molecular basis of amino acid tracer uptake in diffuse glioma are warranted.

P1, N=24, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting

Matched transcriptomic analysis in GLASS pairs supported recurrent-specific reductions in LMNB1, MKI67, and SOX2, with no consistent changes in TP53, HLA-DRA, B2M, or NCAM1. Recurrent IDH-wildtype GBM exhibits a transcriptional and protein expression shift towards a senescence-associated state with no concomitant changes in SOX2 and select immune markers.

Our study established a novel glioblastoma imaging strategy by targeting the IDH1 enzyme, offering a promising alternative approach for fluorescence-guided tumor resection in GBM patients exhibiting high IDH1 expression. Additionally, the probe QM-SO3H can also serve as a valuable visualization tool for investigating IDH1-associated pathophysiology.

In the high-CIN environment of EGFR-amplified GBM, in silico network perturbation suggested that POSTN may function as a candidate modulator of mitotic fidelity, potentially buffering against lethal genomic instability while sustaining rapid clonal evolution. Validated across multicenter cohorts, POSTN showed robust upregulation, strong diagnostic performance (AUC = 0.961), and significant prognostic relevance, emerging as a potential therapeutic vulnerability linking accelerated evolution with immune privilege in the GBM ecosystem.

P2, N=120, Recruiting, University of Birmingham | Trial primary completion date: Apr 2026 --> Sep 2026

To our knowledge, this report is the first to describe a molecularly profiled CCC with somatic VHL inactivation. These results expand the evolving genomic spectrum of CCC beyond its previously known IDH-wildtype status and suggest that VHL pathway dysregulation may contribute to tumorigenesis in a subset of cases.

P1, N=11, Completed, Beijing Tiantan Hospital | Active, not recruiting --> Completed | Trial completion date: Dec 2028 --> Oct 2025

This study demonstrates that increased expression of autophagy-related genes, particularly SQSTM1 and Beclin1, serves as a robust indicator of poor prognosis and shorter survival times in diffuse astrocytic tumors. Furthermore, the elevated expression of Beclin1 and Atg5 in IDH-mutant cases highlights a complex metabolic interplay that warrants further investigation as potential therapeutic targets.